Oropharyngeal Cancer - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 75 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Oropharyngeal Cancer - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Oropharyngeal Cancer - Pipeline Review, H2 2014', provides an overview of the Oropharyngeal Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Oropharyngeal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Oropharyngeal Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Oropharyngeal Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Oropharyngeal Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Oropharyngeal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Oropharyngeal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Oropharyngeal Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Oropharyngeal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Oropharyngeal Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Oropharyngeal Cancer - Overview 7
Pipeline Products for Oropharyngeal Cancer - Comparative Analysis 8
Oropharyngeal Cancer - Therapeutics under Development by Companies 9
Oropharyngeal Cancer - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Oropharyngeal Cancer - Products under Development by Companies 14
Oropharyngeal Cancer - Companies Involved in Therapeutics Development 15
Advaxis, Inc. 15
AstraZeneca PLC 16
AVEO Pharmaceuticals, Inc. 17
Merck & Co., Inc. 18
Novartis AG 19
Serina Therapeutics, Inc. 20
Transgene SA 21
VLPbio 22
Oropharyngeal Cancer - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
ADXS-HPV - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
alpelisib - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ficlatuzumab - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
HNVax - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
olaparib - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
pembrolizumab - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
SER-203 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
TG-4001 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Oropharyngeal Cancer - Recent Pipeline Updates 52
Oropharyngeal Cancer - Dormant Projects 73
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 75
Disclaimer 75

List of Tables
Number of Products under Development for Oropharyngeal Cancer, H2 2014 7
Number of Products under Development for Oropharyngeal Cancer - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Comparative Analysis by Unknown Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Oropharyngeal Cancer - Pipeline by Advaxis, Inc., H2 2014 15
Oropharyngeal Cancer - Pipeline by AstraZeneca PLC, H2 2014 16
Oropharyngeal Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2014 17
Oropharyngeal Cancer - Pipeline by Merck & Co., Inc., H2 2014 18
Oropharyngeal Cancer - Pipeline by Novartis AG, H2 2014 19
Oropharyngeal Cancer - Pipeline by Serina Therapeutics, Inc., H2 2014 20
Oropharyngeal Cancer - Pipeline by Transgene SA, H2 2014 21
Oropharyngeal Cancer - Pipeline by VLPbio, H2 2014 22
Assessment by Monotherapy Products, H2 2014 23
Number of Products by Stage and Target, H2 2014 25
Number of Products by Stage and Mechanism of Action, H2 2014 27
Number of Products by Stage and Route of Administration, H2 2014 29
Number of Products by Stage and Molecule Type, H2 2014 31
Oropharyngeal Cancer Therapeutics - Recent Pipeline Updates, H2 2014 52
Oropharyngeal Cancer - Dormant Projects, H2 2014 73